# A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

> **NCT02371629** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 776 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** NVA237
- **DRUG:** Placebo
- **DRUG:** Salbutamol

## Key facts

- **NCT ID:** NCT02371629
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-24
- **Primary completion:** 2016-11-16
- **Final completion:** 2016-11-16
- **Target enrollment:** 776 (ACTUAL)
- **Last updated:** 2019-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02371629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02371629, "A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02371629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*